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Abstract
Background: Malignant melanoma (MM) patients are at increasing risk of developing second primary cancers (SPCs). We
assessed mortality and risk of SPCs in MM patients with siblings or parents affected with same cancer compared with that of
the general population.
Methods: We used the Swedish Family-Cancer Database to assess relative risks (RRs) and causes of death in SPCs until 2015
in patients with a MM diagnosis between 1958 and 2015. We identified 35 451patients with MM among whom 3212 received a
subsequent diagnosis of SPC. RRs of SPCs after MM diagnosis were calculated stratifying over concordant family history of
cancer in first-degree relatives.
Results: Familial RRs were increased for second melanoma (RR ¼ 19.28, 95% CI ¼ 16.71 to 22.25), squamous cell skin cancer
(RR ¼ 7.58, 95% CI ¼ 5.57 to 10.29), leukemia (RR ¼ 5.69, 95% CI ¼ 2.96 to 10.94), bladder (RR ¼ 4.15, 95% CI ¼ 2.50 to 6.89),
ovarian (RR ¼ 3.89, 95% CI ¼ 1.46 to 10.37), kidney cancer (RR ¼ 3.77, 95% CI ¼ 1.57 to 9.06), cancer of unknown primary (RR ¼
3.67, 95% CI ¼ 1.65 to 8.16), nervous system (RR ¼ 2.88, 95% CI ¼ 1.20 to 6.93), breast (RR ¼ 2.34, 95% CI ¼ 1.92 to 2.84), lung (RR
¼ 2.24, 95% CI ¼ 1.50 to 3.35), and prostate cancer (RR ¼ 2.22, 95% CI ¼ 1.89 to 2.61) with statistical significance. For all cancers,
familial RR was in excess (2.09, 95% CI ¼ 2.02 to 2.16 vs 1.78, 95% CI ¼ 1.69 to 1.87; Ptrend< .0001). Cause of death in MM
patients with SPC is shown to be dependent on the cancer site though SPCs contributed to majority of deaths.
Conclusions: SPCs appear higher with prior family history of cancer and contribute to mortality. SPC was the most common
cause of death in patients with SPC and is almost uniformly the major contributing cause of death for all cancer sites. For
improved survival in MM patients, prevention and early detection of SPCs would be important.
Survival rates among patients with malignant cutaneous mela-
noma (MM) have improved with a resulting increased likelihood
for occurrence of second primary cancers (SPCs). SPCs in
patients with MM account for 5.1% of all SPCs in Sweden and
3.9% in Germany (1). Patients with MM are at an increased risk
of multiple MMs and at least 10 different types of other (discor-
dant) SPCs (2,3). Multiple MMs signal increased familial suscep-
tibility to MM, and multiple cancers, even the discordant ones,
are often associated with genetic predisposition (2,4). Thus,
known cancer syndromes manifesting MM also show an excess
of some other cancers (5). The most common high-risk gene
predisposing to MM is CDKN2A, which is also associated with
pancreatic cancer (5). Germline mutations in breast cancer 1 as-
sociated protein 1 also cause predisposition to MM, but the
mutations are relatively more important in rare cancers (uveal
melanoma and mesothelioma) constituting a novel cancer syn-
drome (5–7). In addition to the high-risk genes, genome-wide
association studies have identified more than 20 loci that pre-
dispose to MM (8). These are involved in pathways related to ne-
vus count, pigmentation, telomere homeostasis, tumor
suppression, and DNA repair; some of these are also associated
with other cancers (9). Family studies have shown that MM is
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associated at the population level with breast, prostate, colorec-
tal, skin squamous cell (SCC), and nervous system cancers
(10,11). Direct evidence on the effect of family history on SPCs
was recently demonstrated in Hodgkin lymphoma where an ex-
cess of second lung, colorectal, and breast cancers was found in
survivors with a family history of these cancers (12). In cancers
with good survival, SPCs are an important cause of death
(13,14).
In the present study, we focus on risk for and mortality in
SPCs and higher order multiple primary cancers in patients
with MM, hypothesizing that family history of cancer X in
patients with MM increases the risk for cancer X as an SPC. A
first-degree family history of any cancer is common in MM
patients because 6.3% of patients have a family member diag-
nosed with MM and 52% of them have a family history of some
other form of cancer (15). We used data from the most recent
version of the Family-Cancer Database, which covers the
Swedish population for more than a century and linked cancers
for 58 years from the national cancer registry. The effect of mul-
tiple primaries, particularly of SPCs, was remarkably high on
disease outcome. Any attempt to increase survival in MM needs
to counter the challenge of SPCs.
Methods
Data for our study were obtained from the Swedish Family-
Cancer Database, which includes information about the resi-
dents of Sweden organized in family datasets and covers more
than a century (16). Individuals were linked to the national can-
cer registry for first and any subsequent cancers (16). The data-
base records cancers according to the International
Classification of Diseases 7th revision (ICD-7) and later revi-
sions. Until the end of 2015, more than 2 million cancers were
recorded among 16.1 million individuals; 8.8 million individuals
belonged to the 0- to 83-year-old offspring generation (born af-
ter 1931) for which relative risks (RRs) were calculated.
Statistical Analysis
We followed newly diagnosed patients with MM from January 1,
1958 until December 31, 2015 for diagnosis of any of the 35
different SPCs, including second MMs. Family history was called
when the SPC was the same, concordant cancer diagnosed in a
first-degree relative (parent or sibling). Family history was
recorded from the beginning of cancer registration in Sweden
from the year 1958 onwards. The follow-up was terminated at
diagnosis of SPC, emigration, death, or December 31, 2015
(when the oldest individuals reached age 83 years), whichever
occurred first. Causes of death were also available in the data-
base as obtained from the national causes of death register.
Familial and nonfamilial RRs of SPC were estimated comparing
risk (incident rate) of SPC among MM survivors, with or without
prior family history, against risk of that cancer in the general
population. Waiting time distribution with Poisson assumption
was employed to estimate RRs and corresponding confidence
intervals (CIs) for 5%, 1%, and 0.1% levels of statistical signifi-
cance. A generalized linear multivariable model was used with
regressors including age group, sex, calendar period, residential
area, and socioeconomic status as adjustments for potential
confounding.
The underlying cause of death is ascertained by amalgam-
ation of the cancer registry and the death certificate notification
(17). This is annotated with the following ICD codes from 1997
onwards: ICD-7 (1958–1968), ICD-8 (1969–1986), ICD-9
(1987–1996), and ICD-10. All cancer-related deaths were strati-
fied into MM, SPC, “other cancer,” and non-neoplastic cause of
death “other causes.” For patients with multiple MMs, it was not
possible to define which MM caused the patient’s death. “Other
cancer” includes cases diagnosed at the issue of death certifi-
cates, referred to as “death certificate notifications” (17–19).
These notifications are not used by the Swedish Cancer Registry
to complement cancer data in contrast to that of the other
Nordic Cancer Registries (17–19). We have found that the notifi-
cations often included multiple cancers and cancer of unknown
primary (CUP). In our previous studies, we have used these as
information on metastases (20,21). If the death certificate notifi-
cation matched the organ site of the reported primary cancer, it
was classified to that site. In some cases when such an assign-
ment could not be made, the classification was considered
“other cancer.”
Survival probabilities and hazard ratios were estimated sub-
ject to conformity to proportional hazard assumption with Cox
regression, adjusted for sex, residential area, and socioeco-
nomic status stratified over diagnosis of SPC and family history
of cancer. Although the nationwide database does not include
data on possible individual risk factors of cancer, adjustment
for socioeconomic status helps to control for a number of social
class-related risk factors, including smoking (22,23). Population
attributable fraction (PAF) was employed to estimate the effect
of family history of cancer on total disease burden. It was
assessed with RRs where PAF ¼ proportion of population with
family history  [1 – RR(fh-) / RR(fhþ)]; RRfh(þ/-) indicates RR with/
without cancer family history. All statistical analyses were done
with R version 3.4 and SAS version 9.4.
The study was approved by the Ethical Committee of Lund
University without requirement for informed consent. Through
advertisements in the major newspapers, people could choose
to opt out before the research database was constructed. The
project database is located at Center for Primary Health Care in
Malmo¨, Sweden.
Results
A total of 8.8 million individuals belonging to the offspring gen-
eration with full parental history contributed to the study co-
hort; 35 451 (47% male) developed MM at 51 years of median age
at diagnosis (Table 1). Among MM survivors, with 6 years of me-
dian follow-up, 4724 (13.3%) developed SPCs including 3212
(67.9%) with a family history of cancer. Of patients with SPC, 823
(17.4%) later went on to develop a third primary cancer, 172
(3.6%) of them developed a fourth primary cancer, and 60 (1.3%)
developed a fifth primary cancer. The total number of deaths by
the end of 2015 among all MM patients was 5259 (14.8%); of
these, 3877 (73.7%) occurred in patients without SPC and 1382
(29.3%) of those with SPCs. In patients without SPC, 74.2% of the
deaths were due to MM, but in patients with SPC only 24.5% of
deaths were due to MM while the majority of deaths (53.1%)
were due to second and higher order multiple primaries.
In Table 2 we compared RRs of SPCs in patients with MM
depending on a family history of concordant cancer (or of
any cancer in the last line). SPCs were listed when two or
more familial cases were found. The RRs were statistically
significant for family history for 11 SPCs, including lung,
breast, ovarian, prostate, kidney, bladder, skin (SCC) and ner-
vous system cancers, melanoma, leukemia, and CUP. The
highest risk for familial SPC was for melanoma (RR familial
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¼19.28 vs RR nonfamilial ¼ 9.21), followed by skin SCC (RR fa-
milial ¼ 7.58 vs RR nonfamilial ¼ 3.50), leukemia (RR familial
¼ 5.69 vs RR nonfamilial ¼ 1.46) and cancers of the bladder
(RR familial ¼ 4.15 vs RR nonfamilial ¼ 1.28), ovary (RR famil-
ial ¼ 3.89 vs RR nonfamilial ¼ 1.07), and kidney (RR familial ¼
3.77 vs RR nonfamilial ¼ 1.50) and CUP (RR familial ¼ 3.67 vs
Table 1. Demographic summary of study population
Total No. of individuals followed 8.8 million
Summary of cases
Number of melanoma diagnoses 35 451
Males 16 659 (47.0%)
Females 18 792 (53.0%)
Median age at first cancer diagnosis, y 51 [40–62]*
SPC diagnoses among melanoma survivors 4724
Median follow-up time until SPC diagnosis, y 6 [2–15]
Number of familial cases of SPC (family history of any cancer) 3212
Median total follow-up time since melanoma diagnosis, y 8 [3–16]
3rd and higher order primaries
3rd primary cancer diagnosis 823
4th primary cancer diagnosis 172
5th primary cancer diagnosis 60
Summary of deaths till end of 2015
Total no. of deaths among melanoma patients 5259 (14.8% of all patient)
Total deaths among patients without SPC 3877 (12.6% of all patient)
Total deaths among patients with SPC 1382 (29.3% of all patient)
Summary of causes of death Patients with SPC Patients without SPC
Deaths due to first primary cancer 339 (24.5%) 2875 (74.2%)
Deaths due to SPC 596 (43.1%) —
Deaths due to higher order multiple primary cancer 138 (10.0%) —
Deaths due to other cancer 100 (7.2%) 156 (4.0%)
Deaths due to other cause 209 (15.1%) 846 (21.8%)
Total deaths 1382 3877
*Square bracket indicates inter-quartile range in years. SPC ¼ second primary cancer.
Table 2. Familial risk of second primary cancers among MM survivors
Number of first degree relatives with cancer at a concordant site
1 0
Second cancer No. RR (95% CI) No. RR (95% CI) Ptrend
Colorectum 31 1.28 (0.90 to 1.83) 246 1.16* (1.02 to 1.31) .29
Liver 2 2.08 (0.52 to 8.32) 39 0.94 (0.69 to 1.29) .23
Pancreas 3 2.54 (0.82 to 7.88) 44 0.85 (0.63 to 1.15) .19
Lung 24 2.24‡ (1.50 to 3.35) 179 1.07 (0.92 to 1.24) .01
Breast 99 2.34 (1.92 to 2.84) 458 1.34‡ (1.22 to 1.47) <.001
Endometrium 4 2.40 (0.90 to 6.40) 75 1.06 (0.85 to 1.33) .16
Ovary 4 3.89† (1.46 to 10.37) 48 1.07 (0.80 to 1.41) .04
Prostate 150 2.22‡ (1.89 to 2.61) 522 1.13† (1.04 to 1.23) <.001
Kidney 5 3.77† (1.57 to 9.06) 74 1.50‡ (1.19 to 1.88) .04
Bladder 15 4.15 (2.50 to 6.89) 110 1.28* (1.06 to 1.54) .01
Melanoma 189 19.28 (16.71 to 22.25) 1182 9.21‡ (8.72 to 9.73) <.001
Skin SCC 41 7.58 (5.57 to 10.29) 321 3.50‡ (3.13 to 3.91) <.001
Nervous system 5 2.88* (1.20 to 6.93) 120 1.79‡ (1.49 to 2.14) .03
Endocrine glands 2 3.51 (0.88 to 14.04) 66 1.77‡ (1.39 to 2.25) .33
Non-Hodgkin Lymphoma 4 2.11 (0.79 to 5.61) 136 1.93‡ (1.63 to 2.29) .19
Leukemia 9 5.69‡ (2.96 to 10.94) 87 1.46‡ (1.18 to 1.80) .03
CUP 6 3.67† (1.65 to 8.16) 122 2.21‡ (1.85 to 2.65) .03
All non-melanoma cancers 2223 1.83‡ (1.75 to 1.91) 1130 1.46‡ (1.37 to 1.56) <.001
All 3212 2.09‡ (2.02 to 2.16) 1512 1.78‡ (1.69 to 1.87) <.001
*P ¼ .05 CI ¼ 95% confidence interval; CUP ¼ cancer of unknown primary; MM ¼ malignant cutaneous melanoma; RR ¼ relative risk; SCC ¼ squamous cell carcinoma;
SPC ¼ second primary cancer
†P ¼ .01.
‡P ¼ .001.
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RR nonfamilial ¼ 2.21). For other SPCs with statistically sig-
nificant excess risks, the familial RRs were consistently more
than 2.0. The largest contributions of familial SPCs were ob-
served for melanoma (n¼ 189), prostate (n¼ 150), and breast
(n¼ 99) cancers. The RR for any familial SPC (n¼ 3212, 68.0%
of all MM patients) was 2.09 (95% CI ¼ 2.02 to 2.16) compared
with 1.78 (95% CI ¼ 1.69 to 1.87) without family history
(n¼ 1512, P< .001). We can estimate that the PAF for family
history was 10.1%, which would account for 477 extra
patients with SPC.
Familial risks for most cancers were higher when MM was
diagnosed in relatively young patients, but because of small
numbers none of the differences were statistically significant
(ie, 95% CIs overlapped; Supplementary Table 1, available on-
line). When the cutoff age for MM diagnosis was 50 years,
patients with a family history of MM showed a risk of 20.11 (95%
CI ¼ 16.49 to 24.52) for the early diagnostic group compared
with 18.43 (95% CI ¼ 14.99 to 22.65) in the late group. The differ-
ence in RRs was relatively large for a family history of lung can-
cer (2.99, 95% CI ¼ 1.69 to 5.27 vs 1.79, 95% CI ¼ 1.01 to 3.16).
When the cutoff was at 60 years, the difference in RRs for lung
cancer was even larger (2.62, 95% CI ¼ 1.67 to 4.11 vs 1.45, 95% CI
¼ 0.60 to 3.48). For family histories of endometrial, ovarian, and
kidney cancers, all MM cases were in the early onset group and
the RRs ranged from 3.58 to 5.72.
Of 1382 deaths in patients with SPC, 596 (43.1%) were due to
SPC and 138 (10.0%) were due to higher order multiple primaries
(Table 3). Only the sites with at least five total deaths are listed
although the total includes all the 35 sites. The cause of death
in MM patients with SPC was highly dependent on the site of
SPC. The highest contributions to causes of death were observed
for lung (87.0%) and pancreatic (86.0%) cancers, multiple mye-
loma (85.0%), and ovarian (81.0%) and esophageal (80.0%) can-
cers. Apart from skin (SCC), endocrine gland, and connective
tissue cancers, SPCs at all the other sites contributed a higher
proportion of deaths compared with MM. For death due to
“other cancer,” CUP showed the highest proportion, 32.7%, fol-
lowed by endometrial (25%), connective tissue, and cervical can-
cers (both 22.2%). These results are summarized for the eight
most common SPCs and all SPCs in Figure 1.
Survival data are shown in Figure 2 for patients with and
without SPC and any family history. There was no difference in
the initial survival rates for patients, with and without SPCs, be-
cause SPCs were diagnosed in the course of time (median to SPC
6 y). However, after approximately 10 years of follow-up, sur-
vival curves diverged with marked poorer survival for patients
with SPC compared with those without while family history
showed a minor negative effect. Compared with a baseline haz-
ard of 1.00 for patients without SPC or family history (n¼ 1374),
the hazard ratio for patients without SPC but with family history
was 1.13 (n¼ 2503; 95% CI ¼ 1.09 to 1.16) and that for patients
with SPC were 1.97 without family history (n¼ 462; 95% CI ¼
1.89 to 2.04) and 2.04 with family history (n¼ 920; 95% CI ¼ 1.99
to 2.10).
Discussion
Using data from the Swedish Family-Cancer Database, the pre-
sent study covered all diagnoses of SPCs in patients with MM
with a maximum possible follow-up of 58 years starting from
1958. The results offered several novel observations of clinical
importance. Firstly, more than two-thirds (68%) of all MM
patients with SPC had a first-degree family history of any
cancer; this increased the risk from 1.78 to 2.09. The familial
risk was moderately higher in MM patients diagnosed at a rela-
tively early age. Secondly, for 11 SPCs, risk of concordant family
history was statistically significantly increased, being remark-
ably high for melanoma (19.28 vs 9.21), which also resulted in
the largest number of familial cases. However, high and statisti-
cally significant familial risks were observed for other cancers,
including prostate, breast, and skin (SCC) cancers. Thirdly, irre-
spective of family history, patients with SPCs experienced in-
creased mortality. Fourthly, mortality was highest for SPCs,
which are known to be fatal as primary cancers. A limitation of
the study was that the oldest individual in the present cohort
reached age 83 years at the end of 2015, and it is likely that addi-
tional SPCs were/will be diagnosed past the follow-up time
whereby the present results may not have been able to catch
the full scope of SPCs in this cohort of patients (1).
SPCs in patients with MM have been reported in many previ-
ous studies as discussed in the introduction. In the present co-
hort, 13.3% of the patients were diagnosed with SPC. Therapy-
related causes of SPCs are likely to be small for MM because sur-
gery is the main mode of treatment for localized disease.
Environmental causes, such as chronic exposure to ultravio-
let radiation, may be an important cause for SPC in skin
(SCC). Family members also share other environmental/be-
havioral risk factors, but not many of these are known to pre-
dispose to MM. Genetic causes could also be plausible, but
among high-risk genes only mutations in cyclin-dependent
kinase inhibitor 2 A CDKN2A are prevalent in MM families
(24). Mutations in other genes, such as cyclin-dependent ki-
nase 4, breast cancer 1 associated protein 1, telomere main-
tenance genes (TERT, POT1, TERF2IP, and ACD), DNA damage
repair genes (PARP1, ATM), and other nevi and pigmentation-
specific genes are rare in MM and predispose to a limited
number of other cancers, yet these mutations may confer a
high risk in the affected individuals (25–27). Thus with the
exception of SPCs in MM and skin (SCC), no known genes or
environmental factors can be invoked to explain the exten-
sive familial association for SPCs. However, data from this
database have shown that there is a general increase in fa-
milial risk in families with multiple diverse cancers (15). A
consistent increased risk of melanoma was reported in fami-
lies where breast, prostate, colorectal, skin, and nervous sys-
tem cancers were diagnosed (10).
Survival was drastically worse for patients with SPC, and
hazard ratios increased from 1.0 in patients without SPCs to 2.0
for patients with SPCs. Family history was a minor predictor of
survival, but family history contributed to increased numbers of
SPCs, accounting for a PAF of 10.1%.
Mortality patterns in MM patients were distinct depending
on diagnosis of SPC. Among MM patients without SPC, 74.2%
died of MM and 21.8% of other causes. On the contrary, 53.1% of
patients with a subsequent primary cancer diagnosis died be-
cause of SPC or higher order primaries and 24.5% of deaths were
due to MM. Deaths due to other cancers accounted for 7.2% of
all casualties; these were ascertained from death certificate
notifications and amounted to only 4.0% in patients without
SPC. It can be suspected that at least some of these other can-
cers may be metastases originating from earlier cancer diagno-
ses. We observed high RRs for CUP in MM patients with or
without a family history. CUP is characterized as fatal meta-
static cancer originating in an unknown site. We have previ-
ously shown familial clustering of several primary tumors,
including MM, with CUP, speculating that the associated famil-
ial cancer may disclose the origin of CUP cells (28,29). Figure 1
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showed that CUP had the largest proportion of deaths due to
other cancer (32.7%).
What are the clinical take-home messages from this study?
SPCs will increase in accordance with increasing survival in
MM, and the present proportion of 13.3% of patients coming
down with a SPC is an underestimate due to incomplete follow-
up time, particularly towards the termination of the study
with the highest incidence of MM. SPCs are often fatal whereas
prevention and early detection may be life-saving. The most
common SPC was MM, and follow-up of MM patients should
be a necessity, and those with a family history should be
flagged. Skin (SCC) cancer is easily surveyed together with
Table 3. Distribution of cause of deaths in patients with MM diagnosed with multiple primary cancers*
2nd primary cancer 1st primary cancer (MM)
Higher order
multiple primary cancers Other cancer Other causes
Cancer No. (%) No. (%) No. (%) No. (%) No. (%)
UAT 7 (36.8) 4 (21.1) 2 (10.5) 2 (10.5) 4 (21.1)
Esophagus 12 (80.0) 2 (13.3) 1 (6.7)
Stomach 9 (64.3) 3 (21.4) 2 (14.3)
Small intestine 4 (40.0) 1 (10.0) 1 (10.0) 1 (10.0) 3 (30.0)
Colorectum 90 (74.4) 9 (7.4) 6 (5.0) 3 (2.5) 13 (10.7)
Liver 19 (70.4) 3 (11.1) 5 (18.5)
Pancreas 37 (86.0) 1 (2.3) 1 (2.3) 2 (4.7) 2 (4.7)
Lung 134 (87.0) 4 (2.6) 6 (3.9) 3 (1.9) 7 (4.5)
Breast 54 (44.6) 22 (18.2) 19 (15.7) 3 (2.5) 23 (19.0)
Cervix 5 (55.6) 2 (22.2) 2 (22.2)
Endometrium 3 (25.0) 1 (8.3) 3 (25.0) 5 (41.7)
Ovary 17 (81.0) 1 (4.8) 1 (4.8) 2 (9.5)
Other female genitals 3 (50.0) 2 (33.3) 1 (16.7)
Prostate 32 (28.8) 28 (25.2) 16 (14.4) 5 (4.5) 30 (27.0)
Kidney 17 (58.6) 8 (27.6) 2 (6.9) 1 (3.4) 1 (3.4)
Bladder 24 (61.5) 5 (12.8) 4 (10.3) 1 (2.6) 5 (12.8)
Melanoma 140 (59.1) 47 (19.8) 7 (3.0) 43 (18.1)
Skin (SCC) 2 (2.9) 28 (40.6) 10 (14.5) 3 (4.3) 26 (37.7)
Nervous system 42 (60.9) 6 (8.7) 6 (8.7) 9 (13.0) 6 (8.7)
Thyroid gland 4 (33.3) 1 (8.3) 3 (25.0) 4 (33.3)
Endocrine glands 2 (15.4) 2 (15.4) 3 (23.1) 2 (15.4) 4 (30.8)
Connective tissue 1 (11.1) 3 (33.3) 2 (22.2) 3 (33.3)
NHL 28 (54.9) 9 (17.6) 4 (7.8) 1 (2.0) 9 (17.6)
Multiple myeloma 17 (85.0) 2 (10.0) 1 (5.0)
Leukemia 12 (35.3) 9 (26.5) 1 (2.9) 3 (8.8) 9 (26.5)
CUP 19 (18.8) 43 (42.6) 2 (2.0) 33 (32.7) 4 (4.0)
Total 596 (43.1) 339 (24.5) 138 (10.0) 100 (7.2) 209 (15.1)
*CUP ¼ cancer of unknown primary; MM ¼malignant cutaneous melanoma; NHL ¼ non-Hodgkin lymphoma; SCC ¼ squamous cell carcinoma; UAT ¼ upper aerodiges-
tive tract.
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Figure 1. Distribution of causes of death for eight common and all second primary cancers together among malignant cutaneous melanoma survivors. CUP ¼ cancer of
unknown primary; SCC ¼ squamous cell carcinoma. Data are presented in Table 3.
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MM. For other common SPCs, prostate and breast cancers, tak-
ing a family history will help to devise and agree on a manage-
ment plan with the patients. A family history of lung cancer
may signal a risk of SPC and advice about smoking could be
appropriate.
In conclusion, we showed that second and higher order mul-
tiple primaries caused more than half of the deaths in MM
patients with an SPC. Family history of lung, ovary, kidney,
bladder, and skin (SCC) cancer and leukemia more than doubled
the risk of SPC. In agreement with previous reports, a family his-
tory of MM led to an almost 20-fold increased risk of second
MM. Mortality was largely governed by the type of SPC. For im-
proved survival in MM, prevention of SPCs should be a primary
target, which should start with a thorough family history fol-
lowing diagnosis of MM.
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